Chemo-radiotherapy and autologous bone marrow transplantation in poor prognosis neuroblastoma

P. Franzonel, D. Scarpati, V. Vitalel, R. Corvó, S. Barral, M. Guenzil, M. Orsattil, G. Dini

Research output: Contribution to journalArticlepeer-review


In Genoa, 39 patients affected by disseminated neuroblastoma, one to twelve years old, were treated with intensive chemotherapy (Vincristine 4 mg/sqm c.i. over 5 days, Melphalan 140 mg/sqm), total body irradiation (TBI) (3.3 Gy for 3 days), and unpurged autologous bone marrow transplantation (ABMT) since October 1984 until November 1987. Thirty-two patients were in complete response (first group) and 7 had residual disease (second group) after an intensive chemotherapy induction regimen. Actuarial overall survival at 38 months is 52% and disease free survival at 30 months is 28% for the first group. Actuarial overall survival at 25 months is instead 14% for the second group related treatment toxicity has not been too high (3 deaths).

Original languageEnglish
Pages (from-to)102-104
Number of pages3
JournalRadiotherapy and Oncology
Issue numberSUPPL. 1
Publication statusPublished - 1990


  • Advanced neuroblastoma
  • Autologous bone marrow transplantation
  • Total body irradiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology


Dive into the research topics of 'Chemo-radiotherapy and autologous bone marrow transplantation in poor prognosis neuroblastoma'. Together they form a unique fingerprint.

Cite this